Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen r&d expenses
Research and development expenses are spending on new products and technology.
Repligen's R&D Expenses for the twelve months ending Sep 30, 2026 was $57.23M, up 10.2% year over year. For fiscal 2025 it was $54.18M, up 25.4% from the year before. Over ten years it grew 25.2% a year on average. The highest annual figure on record is $54.18M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.18M | +25.4% |
| FY2024 | Dec 31, 2024 | $43.20M | +1.1% |
| FY2023 | Dec 31, 2023 | $42.72M | -2.8% |
| FY2022 | Dec 31, 2022 | $43.94M | +28.2% |
| FY2021 | Dec 31, 2021 | $34.27M | +69.8% |
| FY2020 | Dec 31, 2020 | $20.18M | +3.8% |
| FY2019 | Dec 31, 2019 | $19.45M | +22.9% |
| FY2018 | Dec 31, 2018 | $15.82M | +82.4% |
| FY2017 | Dec 31, 2017 | $8.67M | +17.9% |
| FY2016 | Dec 31, 2016 | $7.36M | +28.1% |
| FY2015 | Dec 31, 2015 | $5.74M | +2.3% |
| FY2014 | Dec 31, 2014 | $5.61M | -23.6% |
| FY2013 | Dec 31, 2013 | $7.34M | -41.4% |
| FY2011 | Mar 31, 2011 | $12.53M | -11.5% |
| FY2010 | Mar 31, 2010 | $14.16M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $14.44M | +1.8% |
| Q2 FY2026 | Jun 30, 2026 | $14.42M | +3.2% |
| Q1 FY2026 | Mar 31, 2026 | $14.46M | +19.3% |
| Q4 FY2025 | Dec 31, 2025 | $13.92M | +19.2% |
| Q3 FY2025 | Sep 30, 2025 | $14.18M | +46.0% |
| Q2 FY2025 | Jun 30, 2025 | $13.97M | +32.1% |
| Q1 FY2025 | Mar 31, 2025 | $12.11M | +7.8% |
| Q4 FY2024 | Dec 31, 2024 | $11.68M | +13.5% |
| Q3 FY2024 | Sep 30, 2024 | $9.71M | -8.2% |
| Q2 FY2024 | Jun 30, 2024 | $10.58M | +9.0% |
| Q1 FY2024 | Mar 31, 2024 | $11.24M | -7.5% |
| Q4 FY2023 | Dec 31, 2023 | $10.29M | -7.5% |
| Q3 FY2023 | Sep 30, 2023 | $10.58M | +3.4% |
| Q2 FY2023 | Jun 30, 2023 | $9.71M | -7.0% |
| Q1 FY2023 | Mar 31, 2023 | $12.15M | -0.0% |
| Q4 FY2022 | Dec 31, 2022 | $11.11M | +21.9% |
| Q3 FY2022 | Sep 30, 2022 | $10.23M | +11.7% |
| Q2 FY2022 | Jun 30, 2022 | $10.44M | +24.4% |
| Q1 FY2022 | Mar 31, 2022 | $12.16M | +59.7% |
| Q4 FY2021 | Dec 31, 2021 | $9.12M | +35.7% |
| Q3 FY2021 | Sep 30, 2021 | $9.15M | +107.0% |
| Q2 FY2021 | Jun 30, 2021 | $8.39M | +93.5% |
| Q1 FY2021 | Mar 31, 2021 | $7.61M | +61.9% |
| Q4 FY2020 | Dec 31, 2020 | $6.72M | +30.0% |
| Q3 FY2020 | Sep 30, 2020 | $4.42M | -18.5% |
| Q2 FY2020 | Jun 30, 2020 | $4.34M | -17.1% |
| Q1 FY2020 | Mar 31, 2020 | $4.70M | +29.9% |
| Q4 FY2019 | Dec 31, 2019 | $5.17M | +64.1% |
| Q3 FY2019 | Sep 30, 2019 | $5.43M | +50.7% |
| Q2 FY2019 | Jun 30, 2019 | $5.23M | -9.5% |
| Q1 FY2019 | Mar 31, 2019 | $3.62M | +10.1% |
| Q4 FY2018 | Dec 31, 2018 | $3.15M | +2.7% |
| Q3 FY2018 | Sep 30, 2018 | $3.60M | +80.0% |
| Q2 FY2018 | Jun 30, 2018 | $5.78M | +210.8% |
| Q1 FY2018 | Mar 31, 2018 | $3.29M | +88.7% |
| Q4 FY2017 | Dec 31, 2017 | $3.07M | +50.4% |
| Q3 FY2017 | Sep 30, 2017 | $2.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.86M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.74M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.04M | – |
See a number that looks wrong?